Current treatments for the above-mentioned medical conditions constrict blood vessels in an uncontrolled way, rather than preventing their dilation in the first place, and thus cause hypertension. [3,4]   MTR-104 normalizes the diameter of blood vessels without the "overshooting" that results in excessive constriction and hypertension. Clinical trials in both Western and Eastern Europe have indicated that TrioxBio's NOS inhibitor is safe and well-tolerated.

News & Media

 August 29, 2016:

"The FDA's Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouronium diethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period."

January 17, 2016:

" TrioxBio Inc. submitted  an Orphan-drug designation request to FDA authorities for the treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH)."